Table 1.

Health‐state transitions for therapeutic drug monitoring (TDM)‐guided dosing and fixed dosing

		Fixed dosing		TDM
Health state		n	%	n	%
Imatinib	Cohort	10 000	100	10 000	100
	Not progressed	1424	14	3453	35
	Progressed total	8576	86	6547	65
	• progressed alive	4562	46	4580	46
	• progressed dead	4014	40	1967	20
	Adverse events	731	7	949	9
Imatinib escalated	Cohort	4562	100	4580	100
	Not progressed	1535	34	1895	41
	Progressed total	3027	66	2685	59
	• progressed alive	1473	32	1318	29
	• progressed dead	1554	34	1367	30
	Adverse events	1322	29	1188	26
Sunitinib	Cohort	1473	100	1318	100
	Not progressed	136	9	170	13
	Progressed total	1337	91	1148	87
	• progressed alive	948	64	816	62
	• progressed dead	389	26	332	25
	Adverse events	163	17	141	11
Regorafenib	Cohort	948	100	816	100
	Not progressed	204	22	197	24
	Progressed total	744	78	618	76
	• progressed alive	504	53	425	52
	• progressed dead	240	25	194	24
	Adverse events	431	46	354	43
Best supportive care	Cohort	504	100	425	100
	Alive	18	4	20	5
	Dead	486	96	405	95
Total deaths		6683	67	4264	43